KRAS amplification
|
Melanoma
|
KRAS amplification
|
Melanoma
|
sorafenib Sensitive: B - Late Trials
|
sorafenib Sensitive: B - Late Trials
|
KRAS amplification
|
CRC
|
KRAS amplification
|
CRC
|
EGFR inhibitor Resistant: C3 – Early Trials
|
EGFR inhibitor Resistant: C3 – Early Trials
|
KRAS amplification
|
CRC
|
KRAS amplification
|
CRC
|
cetuximab Resistant: C3 – Early Trials
|
cetuximab Resistant: C3 – Early Trials
|
KRAS amplification
|
CRC
|
KRAS amplification
|
CRC
|
panitumumab Resistant: C3 – Early Trials
|
panitumumab Resistant: C3 – Early Trials
|
KRAS amplification
|
Germ Cell Tumors
|
KRAS amplification
|
Germ Cell Tumors
|
MEK inhibitor Sensitive: C3 – Early Trials
|
MEK inhibitor Sensitive: C3 – Early Trials
|
KRAS amplification
|
NSCLC
|
KRAS amplification
|
NSCLC
|
lorlatinib Resistant: C3 – Early Trials
|
lorlatinib Resistant: C3 – Early Trials
|
KRAS amplification
|
Pancreatic Cancer
|
KRAS amplification
|
Pancreatic Cancer
|
binimetinib Resistant: D – Preclinical
|
binimetinib Resistant: D – Preclinical
|